BDBM350091 (S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-6-yl)(4-methyl-1,4-diazepan-1-yl)methanone::US10208040, Example 5::US10519153, Example 5::US10836763, Example C-4::US11254669, Example 5::US11667637, Example 5::US11713315, Example C-4

SMILES CCc1cc(O)c(F)cc1-c1ccc2c(n[nH]c2c1)-c1nc2C[C@H](N(Cc2[nH]1)C(C)C)C(=O)N1CCCN(C)CC1

InChI Key InChIKey=XUYYMJJOCDSPON-SHYUYHRMSA-N

Data  16 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 350091   

TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.0250nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.0250nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.158nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.158nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.501nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM350091((S)-(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-in...)
Affinity DataKi:  0.501nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent